Lenacapavir: A capsid inhibitor for HIV-1 treatment and
prevention

J 2025

Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention

DE CLERCQ, Erik; Yuya ZHANG; Guangdi LI; Yelin DENG; Ricardo KHOURI et al.

Základní údaje

Originální název

Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention

Autoři

DE CLERCQ, Erik; Yuya ZHANG; Guangdi LI; Yelin DENG; Ricardo KHOURI; Daniel RŮŽEK; Ewelina KRÓL a Li TAN

Vydání

Biochemical Pharmacology, Elsevier Inc. 2025, 0006-2952

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10600 1.6 Biological sciences

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.600 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/25:00141847

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

Lenacapavir; HIV-1 therapy; Pre-exposure prophylaxis; Drug combination; Drug resistance

Štítky

14314010, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 8. 2025 11:19, Mgr. Marie Novosadová Šípková, DiS.

Anotace

V originále

Lenacapavir (GS-6207) is a capsid inhibitor approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced people with multidrug-resistant HIV-1. Here, this study provides a comprehensive overview of lenacapavir, with a particular focus on its long-acting properties, pharmacodynamics, pharmacokinetics, clinical efficacy and safety, and resistance profile. Clinical trials have demonstrated that long-acting lenacapavir is highly effective not only for treating HIV-1 infection but also as a pre-exposure prophylactic agent. The future development of fixed-dose, long-acting combination regimens incorporating lenacapavir and other long-acting antiretroviral agents offers significant potential for durable and effective HIV-1 management in clinical settings.

Citovat

DE CLERCQ, Erik; Yuya ZHANG; Guangdi LI; Yelin DENG; Ricardo KHOURI; Daniel RŮŽEK; Ewelina KRÓL a Li TAN. Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention. Biochemical Pharmacology. Elsevier Inc., 2025, roč. 240, October, s. 117125-117135. ISSN 0006-2952. Dostupné z: https://doi.org/10.1016/j.bcp.2025.117125.

@article{2514077,
   author = {De Clercq, Erik and Zhang, Yuya and Li, Guangdi and Deng, Yelin and Khouri, Ricardo and Růžek, Daniel and Król, Ewelina and Tan, Li},
   article_number = {October},
   doi = {https://doi.org/10.1016/j.bcp.2025.117125},
   keywords = {Lenacapavir; HIV-1 therapy; Pre-exposure prophylaxis; Drug combination; Drug resistance},
   language = {eng},
   issn = {0006-2952},
   journal = {Biochemical Pharmacology},
   title = {Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention},
   url = {https://www.sciencedirect.com/science/article/pii/S0006295225003909},
   volume = {240},
   year = {2025}
}

TY  - JOUR
ID  - 2514077
AU  - De Clercq, Erik - Zhang, Yuya - Li, Guangdi - Deng, Yelin - Khouri, Ricardo - Růžek, Daniel - Król, Ewelina - Tan, Li
PY  - 2025
TI  - Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention
JF  - Biochemical Pharmacology
VL  - 240
IS  - October
SP  - 117125
EP  - 117125
PB  - Elsevier Inc.
SN  - 00062952
KW  - Lenacapavir
KW  - HIV-1 therapy
KW  - Pre-exposure prophylaxis
KW  - Drug combination
KW  - Drug resistance
UR  - https://www.sciencedirect.com/science/article/pii/S0006295225003909
N2  - Lenacapavir (GS-6207) is a capsid inhibitor approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced people with multidrug-resistant HIV-1. Here, this study provides a comprehensive overview of lenacapavir, with a particular focus on its long-acting properties, pharmacodynamics, pharmacokinetics, clinical efficacy and safety, and resistance profile. Clinical trials have demonstrated that long-acting lenacapavir is highly effective not only for treating HIV-1 infection but also as a pre-exposure prophylactic agent. The future development of fixed-dose, long-acting combination regimens incorporating lenacapavir and other long-acting antiretroviral agents offers significant potential for durable and effective HIV-1 management in clinical settings.
ER  -

DE CLERCQ, Erik; Yuya ZHANG; Guangdi LI; Yelin DENG; Ricardo KHOURI; Daniel RŮŽEK; Ewelina KRÓL a Li TAN. Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention. \textit{Biochemical Pharmacology}. Elsevier Inc., 2025, roč.~240, October, s.~117125-117135. ISSN~0006-2952. Dostupné z: https://doi.org/10.1016/j.bcp.2025.117125.

Přehled o publikaci